Background. Papillary thyroid carcinoma (PTC) has relatively indolent behavior, although some tumors recur and disseminate to distant sites. The aggressive biological behavior of PTC is difficult to predict. MicroRNAs (miRNAs) are dysregulated in various tumors types, and some of them serve as markers of poor prognosis. In this study, we evaluated miRNA expression as a marker of more aggressive behavior in PTC. Methods. miRNA array was used to identify a subset of differentially expressed miRNAs between aggressive and nonaggressive PTC. These miRNAs were further validated by real-time RT-PCR in a cohort of 17 PTC with local tumor recurrence or distant metastases and 15 PTC with no extrathyroidal dissemination and correlated with BRAF, RAS, and RET/PTC mutations and MET expression.
Papillary thyroid cancer (PTC) is the most commonly diagnosed thyroid cancer. Although its incidence is increasing, the overall prognosis is very favorable with current 5-year survival rates of [95%.
1 However, a subset of patients not readily identified by histopathologic staging will have aggressive disease characterized by local recurrence and/or distant metastasis. Identification of patients with PTC and an aggressive phenotype can potentially help guide clinical management by optimizing surgery, adjuvant therapy, and long-term follow-up.
MicroRNAs (miRNA) are small, endogenous noncoding RNAs that are negative gene expression regulators and are important in embryonic development. MiRNA expression is tissue specific, and dysregulation of miRNA expression has been described in a variety of tumors including lung, pancreas, breast, and colorectal cancer. 2 More than 700 human miRNAs have been described that regulate up to a third of all genes. 3 In thyroid cancer, miRNA expression pattern depends on cellular origin and degree of tumor differentiation. 4 Several studies have reported upregulation of miR-146b, miR-221, and miR-222 in papillary thyroid carcinoma. [5] [6] [7] [8] [9] [10] We recently identified a set of 7 miRNAs (miR-187, miR-221, miR-222, miR-146b, miR-155, miR-224, and miR-197) that were overexpressed at least 2-fold in PTC compared with benign hyperplastic nodules. 11 Characterization of this panel has diagnostic utility and in fine needle aspiration specimens, upregulation of C3 of the 7 miRNAs in the panel can predict differentiated thyroid cancer with 88% sensitivity and 100% specificity. 11 Our study also showed a correlation between miRNA expression profile and oncogenic mutations known to be associated with thyroid carcinogenesis. The majority ([70%) of PTC have a nonoverlapping genetic alteration, either a BRAF or RAS mutation, or RET/PTC rearrangement, that results in activation of the MAPK signaling pathway. The type of genetic alteration also correlates with tumor phenotype providing important prognostic information. For example, PTC with the BRAF V600E mutation is more likely to have extrathyroidal extension, lymph node metastasis, advanced stage at diagnosis, and need for cervical reoperation. [12] [13] [14] However, BRAF mutations are found in 40%-45% of PTC, and therefore not all BRAFpositive tumors demonstrate an aggressive behavior. Moreover, not all aggressive PTC carry a BRAF mutation. Therefore, identifying new markers of aggressiveness in PTC is of interest and would be important for patient management.
In this study, we aimed to identify miRNAs differentially expressed in patients with more aggressive PTC, such as those with local recurrence and/or distant metastasis compared with PTC patients without those complications on similar follow-up. We also correlated the miRNA expression with genetic mutations known to be associated with thyroid cancer and MET expression, an oncogene commonly overexpressed in PTC.
MATERIALS ND METHODS

Tissue Samples
Snap-frozen tissue from surgically removed thyroid samples was collected at the Department of Pathology, University of Cincinnati, following the University of Cincinnati Institutional Review Board (IRB) approval or obtained through the Cooperative Human Tissue Network (CHTN). Formalin-fixed paraffin-embedded (FFPE) tissues samples were obtained at the Department of Pathology, University of Pittsburgh after IRB approval. All tumors were reviewed by a single pathologist (Y.E.N.) and classified according to the widely accepted diagnostic histologic criteria. 15 For the validation set of cases, after IRB approval we evaluated the clinicopathologic parameters of patients with PTC who were surgically treated at the University of Pittsburgh Medical Center. A cohort of PTC patients with local recurrence or distant metastatic (AG) disease was identified, and a comparison cohort of PTC patients without recurrent or distant metastasis (NAG) disease was pair matched by age at presentation (± 1 year) and by length of clinical follow-up (±6 months).
Nucleic Acid Isolation
Total RNA was isolated using Trizol reagent (Invitrogen, Carlsbad, CA) for snap frozen tissues as previously described. 16 For FFPE tissues, tumor targets were manually microdissected from the 5-lm unstained histologic sections under the guidance of a corresponding H&E slide using an Olympus SZ61 stereo microscope (Olympus, Hamburg, Germany). RNA was isolated using RNeasy FFPE kit (Qiagen, Valencia, CA) to according to manufacturer protocol. RNA yield was determined using the NanoDrop 1000 spectrophotometer (ThermoScientific, Wilmington, DE). RNA integrity was assessed with the Agilent 6000 NANO kit for the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA) and by amplification of small nucleolar RNA RNU44 and GAPDH housekeeping gene. DNA was isolated using the DNeasy Tissue kit on the automated QIAcube (Qiagen, Valencia, CA) instrument.
miRNA Expression Array
Quantitation of expression of 319 mature miRNA was performed using FlexmiR human microRNA pool, version 8 (Exiqon, Vedbaek, Denmark) and analyzed on Luminex 200 (Luminex Corporation, Austin, TX) according to manufacturer instructions. In detail, 2.5 lg total RNA was labeled with biotin using the FlexmiR MicroRNA Labeling Kit (Luminex, Austin, TX) and subsequently hybridized to beads coated with locked nucleic acids (LNA) probes complementary to mature miRNA sequences. All samples were assayed in duplicate. The system calibration was performed using the xMAP calibration control reagents (Luminex, Austin, TX). A blank control set of beads was used to normalize the background value for every individual miRNA. The 5 synthetic controls and 4 small nucleolar RNA (snoRNA) normalization controls were used to adjust mean fluorescence intensities between samples and between runs using the average correction factor for these controls as recommended by the manufacturer. Finally, the miRNA expression in tumor samples was quantitated relatively to normal tissue using Luminex IS software v.2.3 (Luminex, Austin, TX).
miRNA Real-Time RT-PCR
The measurement of the expression levels of individual miRNAs was performed using miRNA sequence specific primers (Applied Biosystems Inc., Foster City, CA) by the real-time RT-PCR-based detection methodology. Briefly, 10 ng of total RNA was reverse transcribed using HighCapacity cDNA Archive kit (Applied Biosystems Inc., Foster City, CA) followed by amplification on ABI 7500 Real-Time PCR System (Applied Biosystems Inc., Foster City, CA). All RT-PCR reactions were performed in triplicate. Small nucleolar RNA RNU44 was used as endogenous control for the normalization of RNA input. miRNA expression levels were calculated by relative quantitation using the ABI 7500 Real-Time PCR SDS 1.2 software (Applied Biosystems Inc., Foster City, CA), and the fold expression changes were determined by 2 -DDCT method. 17 
Detection of Mutations and MET Expression
The DNA was tested for BRAF V600E and K601E, NRAS codon 61, HRAS codon 61, KRAS codons 12 and 13 point mutations using real-time LightCycler PCR and fluorescence melting curve analysis (FMCA) and RET/PTC rearrangements by real-time RT-PCR with primers designed to flank the respective fusion point as previously described. 18 All samples that tested positive for mutations were sequenced using BigDye Terminator Kit on the ABI3130 (Applied Biosystems).
Expression of the MET gene was evaluated by reverse transcription and PCR amplification with gene specific primers (forward primer, 5 0 -GTC GCT TCA TGC AGG TGG TG-3 0 spanned exons 3 and 4 and reverse primer, 5 0 -TGG GAG TCC AGG AGA AAA TTC A-3 0 located in exon 4) and probe (5 0 -FAM-TTT CTC GAT CAG GAC CAT CAA CCC CTC-3BHQ-3 0 ) using QuantiTech Probe RT-PCR Kit (Qiagen, Valencia, CA). GAPDH housekeeping gene was used as normalization control. Briefly, 5-50 ng of total RNA were reverse transcribed and amplified in a 50-lL volume using QuantiTech Probe RT Mix and 40 pmol of each primer and 2 pmol of each hybridization probe. The reverse transcription was carried out at 50°C for 30 min followed by 40 cycles PCR amplification (denaturation at 94°C for 15 s and annealing and extension at 72°C for 60 s).
Statistical Analysis
Differences in miRNA expression levels between groups were evaluated with Wilcoxon two-sample test and paired t test. Statistical analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC). A significance level is set at P B .05, and all P values reported are 2-sided. Agglomerative hierarchical clustering analysis was performed using Cluster software and TreeView software (http://genome-www5.stanford.edu/resources/restech.shtml). 19 
Search for Target Genes
Putative miRNA target genes were identified using miRBase (http://microrna.sanger.ac.uk), TargetScan (http:// genes.mit.edu/targetscan) and PicTar (http://pictar.bio. nyu.edu) target prediction programs.
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RESULTS
MiRNA expression was initially assessed with miRNA array in 12 snap frozen PTC tissues, including 6 aggressive tumors, 6 nonaggressive tumors, and 4 normal thyroid tissues. The aggressive tumors were identified based on the presence of local recurrence and/or distant metastases, and were matched by mutational status (4 BRAF positive, 1 RET/ PTC positive, and 1 tumor with no mutations) to tumors with no such complications after similar length follow-up (mean follow-up 6.1 years). miRNA array analysis for expression of 319 miRNAs revealed a subset of upregulated miRNAs (miR-146b, miR-221, miR-222, miR-155, miR-31) and downregulated miRNAs (miR-153, miR-448, miR-325, miR-382, miR-495, miR-34b, miR-1, miR-144, miR-367, miR-130b, and miR-138) that was seen in all 12 tumors when compared with normal thyroid tissue (Fig. 1a) . However, the levels of expression were different between the aggressive and nonaggressive groups (Fig. 1b) . miR-146b, miR-221, miR-222, and miR-155 were upregulated to a significantly greater degree in aggressive PTCs compared with nonaggressive tumors (P = .0001, .01, .07, and .01, respectively), and miR-1, miR-34b, miR-130b, and miR-138 demonstrated stronger downregulation in aggressive tumors compared with nonaggressive PTCs (P = .08, .001, .07, .3, respectively).
For the validation cohort, 37 PTC patients were selected. A total of 19 PTCs were collected from patients with disease recurrence and/or distant metastasis (AG) and 18 from patients without recurrence or metastasis (NAG) who were selected to match the age and length of clinical follow-up of the AG patients. After nucleic acid isolation, RNA quality control was not adequate for 5 FFPE tissues and these cases were excluded from the study. The remaining 32 PTCs (17 AG and 15 NAG) were analyzed for miRNA expression and the panel of mutations frequently detected in thyroid cancer. The age of patients ranged from 21 to 73 years, and the female:male ratio was 3.3:1. Mutational analysis revealed 16 BRAF V600E mutations, 1 NRAS codon 61 mutation, and 3 RET/PTC rearrangements that were evenly distributed among the 2 study groups. Apart from locoregional recurrence and/or the presence of distant metastasis that defined the AG cohort, there were no differences between the groups with respect to patient demographics, histologic subtype, or AJCC stage at presentation (Table 1) .
Using real-time RT-PCR, expression of the miRNAs that were initially identified by miRNA array to be differentially dysregulated in aggressive and nonaggressive PTC was evaluated in the validation cohort. In concordance with the array data, miR-146b, miR-221, miR-222, and miR-31 were found to be upregulated more than 2-fold in AG PTC compared with NAG tumors, but miR-155 did not show similar dysregulation (Table 2 ). In particular, the expression levels of miR-146b and miR-222 were significantly higher in the AG PTC group (P = .003 and .018, respectively). MiR-1, miR-34b, miR-130b, and miR-138 were found to be downregulated more than 2-fold in AG PTC with significantly stronger downregulation for miR34b (P = .017) and miR-130b (P = .02) when compared with NAG tumors (Table 2) .
We also compared miRNA expression in BRAF-positive AG vs NAG PTCs to address the question if dysregulation of these miRNAs is independent of BRAF mutational status. miR-146b was upregulated more than 2 times higher in aggressive BRAF-positive tumors compared with nonaggressive BRAF-positive tumors (P = .023) ( Table 3 ; Fig. 2 ). Other miRNAs demonstrated a tendency for differential expression in BRAF-positive AG vs NAG tumors, but the levels did not reach statistical significance (Table 3) .
Next, we searched for potential target genes for the downregulated miRNAs using available prediction programs (miRBase, TargetScan, and PicTar). Interestingly, 2 downregulated miRNAs (miR-1 and miR-34b) had MET as a predicted target gene. In the 3 0 UTR of MET, we identified potential binding sites for miR-1 at nucleotides 811-817 and for miR-34b at nucleotides 2379-2385. Moreover, recent reports have demonstrated that MET can be directly regulated by these miRNAs. 22, 23 We then evaluated the expression of the MET gene by RT-PCR in PTC and normal thyroid tissue. MET was found to be overexpressed in all PTC; however, MET expression was significantly stronger in AG PTC compared with NAG tumors (49.4 and 17.7 correspondingly, P = .024) (Fig. 3) . In addition, MET was expressed more than 3 times higher in aggressive PTC positive for BRAF V600E mutation compared with nonaggressive BRAF-positive tumors (75.9 and 24.2, P = .055) (Fig. 3) . therapy. The AJCC staging system is not as accurate for stratifying recurrence risk, which has clinical significance for most PTC patients. This limitation of the staging system is evident in our selected cohorts as we did not observe any significant difference in initial stage between the 2 study groups, even though the aggressive PTC patients eventually developed locoregional recurrence or distant metastatic disease. A number of molecular markers have been studied as candidates for improved tumor prognostication. For example, the BRAF V600E mutation has been associated in a number of studies with aggressive PTC characteristics such as extrathyroidal extension, lymph node metastases, recurrence, decreased survival, and need for cervical reoperation. 12-14 Previously, we demonstrated that patterns of miRNA expression correlate with different histopathologic types of thyroid cancer and with different oncogenic mutations, suggesting that there could be an association between miRNA expression and biological characteristics of PTC.
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Using the miRNA expression assay as an initial screen, we report here that a number of miRNAs are differentially expressed in aggressive PTC, characterized by distant metastasis or recurrent disease after conventional treatment, compared with nonaggressive PTC. After expression levels were quantified and validated in a separate comparison cohort, we observed that aggressive PTCs were characterized by differential upregulation of miR-146b and miR-222 in addition to downregulation of miR-130b and miR-34b. Although there are several studies describing the use of miRNAs to diagnose thyroid cancer and distinguish between the histopathologic variants, this is the first to identify a subset of upregulated and downregulated miRNAs that could have prognostic utility as well.
We also evaluated the validation cohort for the known somatic mutations commonly associated with PTC. Overall, BRAF V600E was more common in our cohort of aggressive PTC but was also present in nonaggressive tumors, suggesting that BRAF status is not the only predictor of aggressive biologic behavior. Within the group of BRAF-positive PTC, we observed differential miRNA expression in the aggressive compared with the nonaggressive tumors. In particular, miR-146b was significantly overexpressed in the BRAF-positive PTC that also had aggressive tumor behavior, suggesting that miR-146b could be an additional prognostic marker. Not all BRAFpositive PTC demonstrate aggressive biologic behavior, and identification of a new marker that is associated with BRAF-positive tumors and poor prognosis could be particularly informative. Chou et al. recently reported an association between BRAF positivity and miR-146b in aggressive PTC. 24 The cellular mechanism contributing to the association between BRAF, miR-146b overexpression, and aggressive PTC is unclear. In vitro overexpression of BRAF V600E has been shown to upregulate genes in the NF-kappa B pathway resulting in apoptotic resistance. 25 In contrast, miR-146b negatively regulates the NF-kappaB pathway, and in breast cancer cell lines, miR-146b upregulation has been shown to actually suppress metastases. 26, 27 However, miR-146b has never been specifically studied in BRAF-positive thyroid cancer cells. It is possible that dysregulation of NF-kappaB is associated with more aggressive tumor variants, and in fact constitutively deregulated NF-kappaB has been seen in anaplastic thyroid cancers. 25 We were interested in evaluating other possible miRNA target genes and found that MET has potential binding sites for miR-34b and miR-1, 2 of the downregulated miRNAs that we identified to be associated with aggressive PTC. Migliore et al. demonstrated that the miRNAs miR-34b, miR-34c, and miR-199a can negatively regulate MET expression. 23 Transfection of human carcinoma cell lines with these miRNAs showed significantly reduced levels of MET mRNA and protein. In addition, their inhibition with antagomiRs was associated with increased expression of MET protein, suggesting their role in regulation of MET expression. Downregulation of miR-1 has been reported in lung cancer and primary human hepatocellular carcinomas. 28, 29 Recently, Duan and colleagues showed that transfection of chordoma cells with miR-1 inhibits cell growth and significantly decreases MET expression. 22 Accordingly, we observed downregulation of miR-34b and miR-1 in aggressive PTCs as well as associated MET overexpression providing a possible mechanism for the observed biologic behavior that warrants further study.
MET proto-oncogene encodes the tyrosine kinase receptor for hepatocyte growth factor, which is found to be overexpressed in many human cancers. In the thyroid gland, MET has been shown to be expressed in PTC, and some studies correlated MET overexpression with aggressive histological features and advanced stage of the disease. [30] [31] [32] Other studies demonstrated an inverse correlation between MET expression and PTC aggressiveness. 33 In this study we report significant overexpression of MET mRNA in aggressive PTCs compared with nonaggressive tumors. Even among BRAF-positive tumors, MET overexpression was associated with aggressive PTC suggesting that this pathway could be independent of BRAF mutational status. Corresponding MET protein overexpression in in vitro thyroid cancer cell lines will be needed to confirm the mechanistic effects of miRNA dysregulation and these studies are in progress. MET expression is of interest for both prognostic as well as therapeutic reasons. Foretinib, a tyrosine kinase inhibitor, has targeted activity for MET and has recently been shown in a phase I trial to be clinically safe. 34 This provides a potential additional therapeutic option for patients with aggressive PTC associated with MET overexpression.
In summary, we demonstrate that a subset of miRNAs is differentially expressed in aggressive compared with nonaggressive papillary thyroid carcinomas and may potentially have prognostic utility in papillary thyroid cancer. Moreover, it appears that miR-146b overexpression is associated with aggressive PTC independent of BRAF mutational status, and its use thus may provide further refinement of the risk stratification of patients with BRAFpositive tumors.
